Presentation is loading. Please wait.

Presentation is loading. Please wait.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Published byTobias Doyle Modified over 8 years ago

Similar presentations

Presentation on theme: "CPTR Overview CPTR 2012 Workshop October 2-4, 2012."— Presentation transcript:

1 CPTR Overview CPTR 2012 Workshop October 2-4, 2012

2 The Challenge 2

3 Accelerate the development of new, safe, and highly effective regimens for TB by enabling early testing of drug combinations. CPTR Mission 3

4 CPTR Working Group Structure [Enter Presentation Title in Insert Tab > Header & Footer4 Data Standards & Integration WG Biomarkers & Clinical Endpoints WG Preclinical & Clinical Sciences WG Modeling and Simulation WG Health Authorities Submission WG Regulatory Science Consortium Research Resources Group Drug Development Coalition Global Regulatory Pathways WG Stakeholder & Community Engagement WG Access & Appropriate Use WG Clinical Trials Infrastructure WG Integrated Sciences Team

5 CPTR Structure Regulatory Science Consortium Research Resources Group Drug Development Coalition ADVISORY PANEL 5

6 CPTR Key Accomplishments: Regulatory Science Consortium CPTR 2012 Workshop October 2-4, 2012

7 CPTR Regulatory Science Consortium Governance [Enter Presentation Title in Insert Tab > Header & Footer7 Regulatory Science Consortium Research Resources Group Drug Development Coalition Coordinating Committee

8 Government/Regulatory participants Non-profit research members Industry members Regulatory Science Consortium Members and Partners 8

9 Regulatory Science Consortium Regulatory Science Consortium Research Resources Group Drug Development Coalition Our role in accelerating the process includes : Identify tools and methods that can bring the most value Reach scientific consensus through sharing of expertise, information and data Proceed to regulatory qualification when appropriate as an outcome 9

10 Regulatory Sciences Structure and Role Regulatory Science Consortium Biomarkers and Clinical Endpoints TB Data Standards and Integration Health Authority Submissions Pre-Clinical and Clinical Sciences Modeling and Simulation Regulatory Authority Input 10

11 [Enter Presentation Title in Insert Tab > Header & Footer11 Biomarkers and Clinical Endpoints Modeling and Simulation TB Data Standard Version 1.0 launched and available for use on CDISC site (3Q2012) TB data repository developed and launched (3Q2012) for remapping of key data sets to the new standard Liquid Culture to be proposed as a predictive or prognostic biomarker for clinical outcome (2Q2012) Letter of Intent submitted to FDA (3Q2012) Evaluation of key pre-clinical efficacy models for early selection of combination partners complete (2Q2012) In vitro hollow fiber model selected and context of use for this tool is under development (3Q2012) Existing TB progression models evaluated and review manuscript submitted (2Q 2012) Develop a PBPK module to evaluate drug distribution in the infected lung [2Q2013 and ongoing] TB Data Standards and Integration Pre-Clinical and Clinical Sciences Key Accomplishments

12 TB Data Standard [Enter Presentation Title in Insert Tab > Header & Footer12 Clinical data standard used/preferred by FDA review divisions Enable data sharing between organizations Enable aggregation and querying of data When implemented from the start, can lower costs acquiring and analyzing data

13 [Enter Presentation Title in Insert Tab > Header & Footer13 Biomarkers and Clinical Endpoints Modeling and Simulation TB Data Standard Version 1.0 launched and available for use on CDISC site (3Q2012) TB data repository developed and launched (3Q2012) for remapping of key data sets to the new standard Liquid Culture to be proposed as a predictive or prognostic biomarker for clinical outcome (2Q2012) Letter of Intent submitted to FDA (3Q2012) Evaluation of key pre-clinical efficacy models for early selection of combination partners complete (2Q2012) In vitro hollow fiber model selected and context of use for this tool is under development (3Q2012) Existing TB progression models evaluated and review manuscript submitted (2Q 2012) Develop a PBPK module to evaluate drug distribution in the infected lung [2Q2013 and ongoing] TB Data Standards and Integration Pre-Clinical and Clinical Sciences Key Accomplishments

14 Modeling and Simulation Work Group Continuously revise and refine with relevant data (summary and subject-level) Hollow fiber model Physiologically- based PK models Clinical trial simulation tools (drug-disease-trial models) Preclinical PKPD Right Molecule Vision: More efficient translation between each stage of drug development Clinical Pharmacology Right Dose Pharmaco- metrics Right Patients Pharmacology Right Target Network Biology Right Pathway Target Drug Disease 14

15 Today: CPTR 2012 Workshop Today: CPTR 2012 Workshop CPTR 2013 Workshop TB Data Standards v 1.0 Published TB Data Standards Repository Launched Remap TB Data & Load to Repository S22, 27, 28 Publish DPM-WG papers Publish Preclinical Sciences Papers Submit LOI to FDA for Hollow Fiber Qualification Begin Briefing Package for Hollow Fiber Qualification Identify Next Set of DDTs for Qualification Begin Briefing Package for Liquid Culture Qualification Submit LOI to FDA for Liquid Culture Qualification Milestone Horizon 15

16 Research Resources [Enter Presentation Title in Insert Tab > Header & Footer16

17 CPTR Structure Regulatory Science Consortium Research Resources Group Drug Development Coalition 17

Download ppt "CPTR Overview CPTR 2012 Workshop October 2-4, 2012."

Similar presentations

The Drug Discovery Process

The Drug Discovery Process
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
BME-IDEA Workshop, September 28, 2005

BME-IDEA Workshop, September 28, 2005
NHLBI Strategic Visioning Process: Charting Our Future Together

NHLBI Strategic Visioning Process: Charting Our Future Together
The Statisticians Role in Pharmaceutical Development

The Statisticians Role in Pharmaceutical Development
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Approaches to incorporating pharmacoeconomic data into early drug discovery Kevin Sheehy Acting CEO Medicines New Zealand.

Approaches to incorporating pharmacoeconomic data into early drug discovery Kevin Sheehy Acting CEO Medicines New Zealand.
Exploring Collaborations: Successful Strategies for Increasing Equity and Access to STEM Strategy Session 1: Overview and Game Plan 1.

Exploring Collaborations: Successful Strategies for Increasing Equity and Access to STEM Strategy Session 1: Overview and Game Plan 1.
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Sierra Leone Consortium for Relief and Development (CORAD) CARE Int., AFRICARE, Catholic Relief Services, World Vision Int. Action Plan for Making Monitoring.

Sierra Leone Consortium for Relief and Development (CORAD) CARE Int., AFRICARE, Catholic Relief Services, World Vision Int. Action Plan for Making Monitoring.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Closing Remarks CPTR 2012 WORKSHOP Carol Nawina Nyirenda – Patient Advocate Executive Director Community Initiative for TB, HIV/AIDS & Malaria (CITAM+),

Closing Remarks CPTR 2012 WORKSHOP Carol Nawina Nyirenda – Patient Advocate Executive Director Community Initiative for TB, HIV/AIDS & Malaria (CITAM+),
Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.

Introduction to Standard 2: Partnering with consumers Advice Centre Network Meeting Nicola Dunbar October 2012.
Specimen-Related Classes in BRIDG BRIDG Overview for HL7 O&O WG Conference Call July 1, 2015 Wendy Ver Hoef NCI Contractor.

Specimen-Related Classes in BRIDG BRIDG Overview for HL7 O&O WG Conference Call July 1, 2015 Wendy Ver Hoef NCI Contractor.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.
Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.
Leveraging Data Sharing Klaus Romero MD MS FCP Director of Clinical Pharmacology Critical Path Institute.

Leveraging Data Sharing Klaus Romero MD MS FCP Director of Clinical Pharmacology Critical Path Institute.
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

Similar presentations

Ads by Google